Dino Klisovic, MD
Retina Specialist · Dublin, OHNPI 1477644573
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $17,476 of the $20,987 with a category attached, or 83.3%. US Retina LLC accounts for 83.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $7,693 and has fallen 85.5% since, to $1,113 in 2025.
Across 173 payments — averaging $121.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$17K
- Mallinckrodt Hospital Products Inc.$1K
- Regeneron Healthcare Solutions, Inc.$722
- Genentech USA, Inc.$489
- Alimera Sciences, Inc.$292
- Apellis Pharmaceuticals, Inc.$226
- plus $778 from 12 others
What the payments were for
- Food & beverage$3,41216%
- Education$990%
- Ownership interest$17,47683%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $17,476 |
| Mallinckrodt Hospital Products Inc. | 55 | $1,004 |
| Regeneron Healthcare Solutions, Inc. | 24 | $722 |
| Genentech USA, Inc. | 25 | $489 |
| Alimera Sciences, Inc. | 16 | $292 |
| Apellis Pharmaceuticals, Inc. | 9 | $226 |
| AbbVie(2 entities) | 11 | $209 |
| ANI Pharmaceuticals, Inc. | 6 | $154 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $74 |
| Astellas Pharma US Inc | 2 | $67 |
| Sandoz | 2 | $61 |
| Bausch & Lomb Americas Inc. | 3 | $54 |
| Amgen | 3 | $46 |
| Biotissue Holdings Inc. | 2 | $30 |
| Biogen | 1 | $30 |
| Coherus Oncology, Inc. | 1 | $20 |
| Novartis | 1 | $16 |
| Eyepoint US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$129
How this compares
$20,987 in reported general payments places this provider in the 75th percentile of 69 retina specialist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 24 | $2,107,710 |
| LeukeranChlorambucil | 12 | $1,069,906 |
| Humira(Cf) PenAdalimumab | 22 | $217,948 |
| Mycophenolate Mofetil | 209 | $21,705 |
| RestasisCyclosporine | 11 | $13,579 |
| ValacyclovirValacyclovir Hcl | 192 | $9,969 |
| Cyclosporine ModifiedCyclosporine, Modified | 24 | $5,442 |
| Prednisolone Acetate | 117 | $3,332 |
| Atropine Sulfate | 110 | $3,201 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 199 | $2,318 |
| Timolol Maleate | 320 | $2,296 |
| Latanoprost | 169 | $1,307 |
| Brimonidine Tartrate | 131 | $1,290 |
| Doxycycline Hyclate | 42 | $1,246 |
| Azathioprine | 40 | $1,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $1,004 | $2,107,71024 claims |
| AbbVieRestasis | $209 | $13,57911 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $74 | $92116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 69 retina specialist providers in Ohio.
Other retina specialist in Dublin
- Louis ChorichDublin$40K
- Sugat PatelDublin$33K
- Dominic BuzzaccoDublin$12K
- Vishal ParikhDublin$11K
- Johnstone KimDublin$10K
- Joseph ConeyBeachwood$980K
- Sumit SharmaCleveland$428K
- Aleksandra RachitskayaCleveland$303K
- David MillerBeachwood$299K
- Katherine TalcottCleveland$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.